Did regulators jump the gun on febuxostat?

Rheumatologists are raising issues with interpretation of the CARES trial

Safety warnings on the increased heart risk posed by gout drug febuxostat are being queried by rheumatologists who have noted that discontinuation of the drug is also associated with excess mortality.